Skip to main content

Table 3 Duration of edoxaban interruption (days) for major and nonmajor surgeries

From: Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE study

Time of interruption  relative to procedurea

Major surgeries

(n = 274)b, c

Nonmajor surgeriesd

(n = 512)

P-value from Wilcoxon test

Pre- and postprocedure

  

< 0.0001

 Median

4

1

 

 Mean ± SD

9.0 ± 10.6

2.8 ± 5.3

 

Preprocedure

  

< 0.0001

 Median

2

1

 

 Mean ± SD

2.2 ± 1.8

1.3 ± 1.5

 

Postprocedure

  

< 0.0001

 Median

2

0

 

 Mean ± SD

7.0 ± 9.7

1.5 ± 4.7

 
  1. Data shown are number of days
  2. n Number of surgeries, SD Standard deviation
  3. aGroups include surgeries without interruption
  4. bPostprocedural interruption, n = 267
  5. cFor 2 surgeries, data for edoxaban use on the date of the surgery are unavailable
  6. dPostprocedural interruption, n = 507
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us